(Q47335694)

14 January 2018

title

Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study (English)

1 reference

14 January 2018

0 references

1 reference

Massicotte P

1

1 reference

14 January 2018

Adams M

2

1 reference

14 January 2018

Marzinotto V

3

1 reference

14 January 2018

Brooker LA

4

1 reference

14 January 2018

Andrew M

5

1 reference

14 January 2018

language of work or name

English

0 references

publication date

1 March 1996

1 reference

14 January 2018

The Journal of Pediatrics

published in

1 reference

14 January 2018

volume

128

1 reference

14 January 2018

issue

3

1 reference

14 January 2018

page(s)

313-318

1 reference

14 January 2018

Use of heparin in newborn infants

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Anticoagulant therapy by continuous heparinization in newborn and older infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Heparin therapy in pediatric patients: a prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

The comparison of the pharmacokinetics of a low molecular weight heparin in the newborn and adult pig.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Heparin clearance and ex vivo recovery in newborn piglets and adult pigs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Heparin clearance in the newborn

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

A Standard Heparin Nomogram for the Management of Heparin Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Coagulation Studies in Extremely Premature Infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Red blood cells: their dual role in thrombus formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Management of major thromboembolic complications of umbilical artery catheters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Thrombotic disease in newborn infants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Neonatal thrombotic disease: prevention, diagnosis, and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Isolation and characterization of oligosaccharides obtained from heparin by the action of heparinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Anticoagulant activity of heparin: isolation of antithrombin-binding sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Molecular weight dependence of the anticoagulant properties of heparin: intravenous and subcutaneous administration of fractionated heparins to man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Pharmacokinetics of fragmin. A comparative study in the rabbit of its high and low affinity forms for antithrombin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Anticoagulant Activities of High and Low Molecular Weight Heparin Fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. The European Fraxiparin Study (EFS) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. H.B.P.M. Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2896%2970273-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-3476(96)70273-1

1 reference

14 January 2018

PubMed ID

8774496

1 reference

14 January 2018